Acta Psychiatrica Scandinavica
September 8, 2023
Giacomo D’andrea, Mauro Pettorruso, T. Rhee et al.
8 citations
Depressive disorders represent a significant economic and health burden globally. This is particularly evident in treatment-resistant depression (TRD), commonly defined as the absence of a satisfactory response to at least two different antidepressant trials (as defined by the U.S. Food and Drug Administration/FDA and European Medicine Agencies/EMA). The foregoing TRD cases frequently manifest...
Clinical Psychopharmacology and Neuroscience
September 6, 2023
Julia Vendrell-Serres, Oscar Soto-Angona, Amanda Rodríguez‐Urrutia et al.
8 citations
Objective: : Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more anti-depressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were...
The Brown University Psychopharmacology Update
September 1, 2023
Interim results from a Phase 3 study of esketamine nasal spray in patients with treatment‐resistant depression showed no emerging safety concerns and sustained improvement in depressive symptoms. Nearly half of study participants met criteria for remission at the end of the study's optimization/maintenance phase, the investigators reported. Study results were published online May 12, 2023, in...
Research Square
August 28, 2023
preprint
Abstract: After resolution of primary infection, patients are susceptible to more severe secondary infection with unclear underlying mechanisms.To investigate whether esketamine treatment immediately after primary LPS exposure could alleviate second-infection-induced cognitive impairment. In this study, mice were injected intraperitoneally (i.p.) with lipopolysaccharides (LPS; 5 mg/kg) 10 days...
Trials
August 19, 2023
Kaili Yu, Zhenguo Song, Bowen Zhang et al.
Pancreatoduodenectomy (PD) is traumatic, difficult to perform, and has a high incidence of postoperative complications and perioperative mortality. Postoperative complications and pain occur frequently and seriously affect the psychological status of patients. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has analgesic and antidepressant effects. In this study, we aim to...
Asian Journal of Nursing Education and Research
August 15, 2023
V. Nirosha, V. Gayathri
Depression is more than feeling a little sad or "blue" for a few days. Antidepressant medications are used in the treatment of clinical depression, usually alongside other forms of therapy such as psychological or behavioral therapy. Spravato is a medicine used to treat adults with major depression that is resistant to treatment. (Bahr, 2019) It is used in combination with an SSRI or SNRI...
Trials
August 13, 2023
Irina Falkenberg, Florian Bitsch, Wei Liu et al.
4 citations
Abstract Background Major depressive disorder (MDD) is a highly prevalent (8–15%), severely disabling disorder and is associated with enormous socioeconomic impact. Antidepressant medication for the treatment of MDD has proven effective in RCTs; however, placebo response is also substantial. Given the potential benefits of modulating the placebo response in patient care and pharmacological...
BMC Psychiatry
August 11, 2023
Abstract: Background: Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. In pooled analyses of two pivotal phase 3 studies, ASPIRE I and II, remission rates were consistently higher among patients with MDD with active suicidality who...
Bipolar Disorders
August 10, 2023
Renato de Filippis received travel grants and/or speaker/consultant fees from Janssen-Cilag. Pasquale De Fazio declares that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Please...
CNS Drugs
August 9, 2023
Meredith Castro, Samuel T. Wilkinson, Rayan K. Al Jurdi et al.
Background: Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 evaluated patients with TRD who received a second induction (IND) and maintenance treatment with ESK...
Current Medical Research and Opinion
August 3, 2023
OBJECTIVE: To describe access and real-world use patterns of esketamine nasal spray among adults with treatment-resistant depression (TRD) with private or public insurance. METHODS: Adults with ≥1 claim for esketamine nasal spray were selected from Clarivate's Real World Data product (January 2016-March 2021). Patients with evidence of TRD initiating esketamine (index date) after 05 March 2019...
JAMA Network Open
August 1, 2023
Chunfeng Xiao, Jia Zhou, Anning Li et al.
Importance: Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies. Objective: To assess the efficacy and safety of a single subanesthetic dose of esketamine in boosting the efficacy of oral...
Psychiatry Research
July 29, 2023
Mauro Pettorruso, Roberto Guidotti, Giacomo D’andrea et al.
56 citations
Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data about predictors of response are still lacking. Thus, a tool that can predict the individual patients' probability of response to ESK-NS is needed. This study investigates sociodemographic and...
Computational and Mathematical Methods in Medicine
July 26, 2023
Computational And Mathematical Methods In Medicine
[This retracts the article DOI: 10.1155/2022/1524198.].
Neuropsychiatric Disease and Treatment
July 17, 2023
Cheng-Chuan Chen, Xiao-Bin Wang
Thank you very much for your attention and advice, as this is indeed a thought-provoking issue. Although the US Food and Drug Administration (FDA) has not yet recognized the advantages of ketamine in treating depression and preventing suicide, relevant research results show that ketamine also has a significant role in preventing suicide. In contrast, as the only drug approved by the FDA,...
Neuropsychiatric Disease and Treatment
July 12, 2023
Lucian Manu
Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis." This letter is not a rebuttal to the article but, rather, a response to further clarify a few points on the real-world use of ketamine and esketamine.
International Clinical Psychopharmacology
July 11, 2023
Lucas Arrighi, Eloïse Maakaron, Théo Korchia et al.
About 30% of patients with major depressive disorder have treatment-resistant depression (TRD). Recently, intranasal esketamine was approved as a treatment option after the failure of two antidepressant trials. We report a patient with multiresistant depression that was successfully and safely treated with esketamine nasal spray. This 31-year-old inpatient with severe, chronic, and multi-TRD...
American Journal of Geriatric Psychiatry
July 8, 2023
Giacomo D’andrea, Stefania Chiappini, Roger S McIntyre et al.
36 citations
INTRODUCTION: Treatment-resistant depression (TRD) is a serious and debilitating psychiatric disorder that frequently affects older patients. Esketamine nasal spray (ESK-NS) has recently been approved as a treatment for TRD, with multiple studies establishing its efficacy and tolerability. However, the real-world effectiveness, tolerability, and safety of this treatment in older adults is still...
International Clinical Psychopharmacology
July 7, 2023
Nicola Ragone, Barbara Barbini, Carolina Passani et al.
More than 10 years ago, the discovery of the antidepressant effects of Ketamine opened the opportunity to develop a novel class of antidepressants. Ketamine induces dissociative symptoms as a major side effect. This rapid-acting antidepressant is available as an endovenous racemic compound and as an intranasal S-enantiomer: Esketamine; which is four-fold more potent for the NMDA receptor. Here...
Journal of Psychiatric Practice
July 1, 2023
Maria Pepe, Giovanni Bartolucci, Ilaria Marcelli et al.
Background: Cognitive symptoms are a core feature of depressive disorders, interfere with full functional recovery and are prominent in patients with treatment-resistant depression (TRD), particularly in severe chronic cases. Intranasal (IN) esketamine was recently approved for the treatment of TRD; however, its effects on cognitive symptoms are unclear. In this article, we describe cognitive...